Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2018 February;153(1) > Giornale Italiano di Dermatologia e Venereologia 2018 February;153(1):26-32

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

A Journal on Dermatology and Sexually Transmitted Diseases


Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,311


eTOC

 

ORIGINAL ARTICLE  


Giornale Italiano di Dermatologia e Venereologia 2018 February;153(1):26-32

DOI: 10.23736/S0392-0488.16.05384-0

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

UV-selective face cream (Acne RA-1,2) in acne patients: clinical study of its effects on epidermal barrier function, sebum production, tolerability and therapy adherence

Giuseppe MONFRECOLA , Claudia CAPASSO, Giuseppe RUSSO, Gabriella FABBROCINI

Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy


PDF  


BACKGROUND: General skin care recommendations such as the use of moisturizers and products with adequate photoprotection are important components of management for acne patients to complement the medical regimen. This study aimed to evaluate the real-life clinical effects of a novel UV-selective face cream (Acne RA-1,2, Meda Pharma, Solna, Sweden) on acne, epidermal barrier function, sebum production, adherence and tolerability when used together with pharmacological acne treatment.
METHODS: Forty patients receiving pharmacological acne treatment applied Acne RA-1,2 once-daily for three months. Investigator’s Global Assessment of acne, trans-epidermal water loss, sebum production and tolerability were assessed at one and three months.
RESULTS: After 3 months, there was a 38% significant clinical improvement in mean Investigator Global Assessment score (3.4 to 2.1), a 29% significant reduction in trans-epidermal water loss (13.2 to 9.4 g/h/m2), and a 17% significant decrease in sebum production vs. baseline (234.6 to 195.6 µg/cm2; all P<0.01). One hundred percent of patients reported complete adherence to pharmacological therapy over the summer of the study vs. 52.5% in the previous summer. About 87.5% of patients considered their acne improved over the summer of the study, vs. 55.0% in the previous summer. Pruritus, erythema, dryness and total tolerability symptom scores were significantly reduced after 3 months vs. baseline (P<0.05).
CONCLUSIONS: Acne RA-1,2 is a useful daily adjunct to pharmacological therapy as it helps to mitigate the irritation these therapies cause, increasing adherence to therapy, and leading to a clinical improvement in acne and epidermal barrier function and a decrease in sebum production.


KEY WORDS: Acne - Medication adherence - Cosmeceuticals - Sebum

top of page

Publication History

Issue published online: January 8, 2018
Article first published online: June 10, 2016
Manuscript accepted: May 30, 2016
Manuscript received: April 27, 2016

Cite this article as

Monfrecola G, Capasso C, Russo G, Fabbrocini G. UV-selective face cream (Acne RA-1,2) in acne patients: clinical study of its effects on epidermal barrier function, sebum production, tolerability and therapy adherence. G Ital Dermatol Venereol 2018;153:26-32. DOI: 10.23736/S0392-0488.16.05384-0

Corresponding author e-mail

giuseppe.monfrecola@unina.it